Key Points
- Vaxcyte insider Harpreet Dhaliwal sold 17,000 shares for $935,000 at an average price of $55.00 under a pre-arranged Rule 10b5-1 plan, reducing their ownership by 18.13% to 76,756 shares.
- The company reported a quarterly loss of $1.97 per share, beating analyst expectations of a $2.06 loss. Vaxcyte also held approximately $2.5 billion in cash, equivalents and investments as of June 30, 2026.
- Analyst sentiment remains mixed: six analysts rate the stock a Buy, one a Hold and two a Sell, resulting in a consensus Hold rating despite an average price target of $86.00. Investors are also awaiting Phase 3 VAX-31 trial data beginning in the fourth quarter of 2026.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 2,250 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00. Following the completion of the sale, the chief operating officer directly owned 157,541 shares of the company's stock, valued at $8,485,158.26. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50.
- On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00.
Vaxcyte Stock Performance
Vaxcyte stock opened at $55.92 on Thursday. The firm has a market cap of $8.07 billion, a PE ratio of -8.13 and a beta of 1.23. The firm's 50 day moving average price is $53.56 and its two-hundred day moving average price is $55.10. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the company posted ($1.22) earnings per share. Equities analysts anticipate that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of PCVX. Royal Bank of Canada raised its holdings in shares of Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock valued at $1,113,000 after purchasing an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Vaxcyte in the first quarter worth $219,000. Caxton Associates LLP acquired a new position in Vaxcyte during the first quarter worth $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock worth $19,409,000 after buying an additional 41,034 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company's stock valued at $250,000 after buying an additional 932 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.
Key Vaxcyte News
Here are the key news stories impacting Vaxcyte this week:
- Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
- Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
- Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
- Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
- Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on PCVX. Weiss Ratings reissued a "sell (d-)" rating on shares of Vaxcyte in a research report on Monday, July 6th. Zacks Research lowered Vaxcyte from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen downgraded Vaxcyte from a "sell" rating to a "strong sell" rating in a research note on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $86.00.
Get Our Latest Stock Analysis on PCVX
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
